Related Experiment Video
Updated: Jun 17, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids
Walter T Lee1, Chunrui Tan, Gary Koski
1Division of Otolaryngology-Head and Neck Surgery, Duke University Medical Center, Durham, North Carolina, USA. walter.lee@duke.edu
Background:
Tumor-associated antigens (TAAs) are known to be immunotherapy targets; thus tumor-sharing TAA may be used as a fusion hybrid partner to confer protection against subsequent tumor challenge.
Methods:
The squamous cell carcinomas (SCCs), SCCVII and B4B8, were used in C3H/HEN mice: SCCVII (H-2(k)) is syngeneic, B4B8 (H-2(d)) is allogeneic. Experiments using tumor alone included hyperimmunization schedule, subdermal and intranodal routes. Mice were challenged 2 weeks later. Fusion hybrids were created from both SCC tumor cell lines and syngeneic dendritic cells (DCs). These were delivered intranodally for immunization, and mice were challenged with tumor 2 weeks later.
Results:
Only syngeneic tumor given subdermally was able to protect after tumor challenge 2 weeks later. Hyperimmunization schedule did not alter these findings. However, fusion hybrid immunization from both allogeneic and syngeneic SCCs conferred protection after tumor challenge.
Conclusions:
Allogeneic tumor-DC fusion hybrids targeting TAA can protect against subsequent tumor challenge.
Insights
Tumor-associated antigen (TAA) fusion hybrids, even allogeneic ones, effectively protected mice against subsequent tumor challenge. This immunotherapy approach offers a promising strategy for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Tumor-associated antigens (TAAs) are key targets for cancer immunotherapy.
- Utilizing shared TAAs in fusion hybrids may enhance protection against tumor recurrence.
Purpose of the Study:
- To investigate the efficacy of tumor-dendritic cell (DC) fusion hybrids in conferring protection against subsequent tumor challenge.
- To evaluate both syngeneic and allogeneic fusion hybrids as potential cancer vaccines.
Main Methods:
- Squamous cell carcinoma (SCC) cell lines (syngeneic SCCVII and allogeneic B4B8) were used in C3H/HEN mice.
- Fusion hybrids were created between SCC tumor cells and syngeneic dendritic cells (DCs).
- Mice were immunized intranodally with fusion hybrids and challenged with tumor 2 weeks later.
Main Results:
- Intranodal immunization with syngeneic or allogeneic SCC-DC fusion hybrids conferred protection against tumor challenge.
- Subdermal injection of syngeneic tumor alone provided protection, but hyperimmunization schedules did not improve outcomes.
- Fusion hybrid immunization proved effective regardless of tumor allogeneicity.
Conclusions:
- Allogeneic tumor-DC fusion hybrids targeting TAAs can induce protective immunity against subsequent tumor challenge.
- This approach represents a viable strategy for developing effective cancer vaccines.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...